Ditte Eklund Nygaard

Deviations in delineated GTV caused by artefacts in 4DCT

BACKGROUND AND PURPOSEnFour-dimensional computed tomography (4DCT) is used for breathing-adapted radiotherapy planning. Irregular breathing, large tumour motion or interpolation of images can cause artefacts in the 4DCT. This study evaluates the impact of artefacts on gross tumour volume (GTV) size.nnnMATERIAL AND METHODSnIn 19 4DCT scans of patients with peripheral lung tumours, GTV was delineated in all bins. Variations in GTV size between bins in each 4DCT scan were analysed and correlated to tumour motion and variations in breathing signal amplitude and breathing signal period. End-expiration GTV size (GTVexp) was considered as reference for GTV size. Intra-session delineation error was estimated by re-delineation of GTV in eight of the 4DCT scans.nnnRESULTSnIn 16 of the 4DCT scans the maximum deviations from GTVexp were larger than could be explained by delineation error. The deviations were largest in the bins adjacent to the end-inspiration bin. The coefficient of variation of GTV size was significantly correlated to tumour motion in the cranio-caudal direction, but no significant correlation was found to breathing signal variations.nnnCONCLUSIONnWe found considerable variations in GTV size throughout the 4DCT scans. Awareness of the error introduced by artefacts is important especially if radiotherapy planning is based on a single 4DCT bin.

ARTIFACTS IN CONVENTIONAL COMPUTED TOMOGRAPHY (CT) AND FREE BREATHING FOUR-DIMENSIONAL CT INDUCE UNCERTAINTY IN GROSS TUMOR VOLUME DETERMINATION

PURPOSEnArtifacts impacting the imaged tumor volume can be seen in conventional three-dimensional CT (3DCT) scans for planning of lung cancer radiotherapy but can be reduced with the use of respiration-correlated imaging, i.e., 4DCT or breathhold CT (BHCT) scans. The aim of this study was to compare delineated gross tumor volume (GTV) sizes in 3DCT, 4DCT, and BHCT scans of patients with lung tumors.nnnMETHODS AND MATERIALSnA total of 36 patients with 46 tumors referred for stereotactic radiotherapy of lung tumors were included. All patients underwent positron emission tomography (PET)/CT, 4DCT, and BHCT scans. GTVs in all CT scans of individual patients were delineated during one session by a single physician to minimize systematic delineation uncertainty. The GTV size from the BHCT was considered the closest to true tumor volume and was chosen as the reference. The reference GTV size was compared to GTV sizes in 3DCT, at midventilation (MidV), at end-inspiration (Insp), and at end-expiration (Exp) bins from the 4DCT scan.nnnRESULTSnThe median BHCT GTV size was 4.9 cm(3) (0.1-53.3 cm(3)). Median deviation between 3DCT and BHCT GTV size was 0.3 cm(3) (-3.3 to 30.0 cm(3)), between MidV and BHCT size was 0.2 cm(3) (-5.7 to 19.7 cm(3)), between Insp and BHCT size was 0.3 cm(3) (-4.7 to 24.8 cm(3)), and between Exp and BHCT size was 0.3 cm(3) (-4.8 to 25.5 cm(3)). The 3DCT, MidV, Insp, and Exp median GTV sizes were all significantly larger than the BHCT median GTV size.nnnCONCLUSIONSnIn the present study, the choice of CT method significantly influenced the delineated GTV size, on average, leading to an increase in GTV size compared to the reference BHCT. The uncertainty caused by artifacts is estimated to be in the same magnitude as delineation uncertainty and should be considered in the design of margins for radiotherapy.

Respiration-Correlated Image Guidance Is the Most Important Radiotherapy Motion Management Strategy for Most Lung Cancer Patients

PURPOSEnThe purpose of this study was to quantify the effects of four-dimensional computed tomography (4DCT), 4D image guidance (4D-IG), and beam gating on calculated treatment field margins in a lung cancer patient population.nnnMATERIALS AND METHODSnImages were acquired from 46 lung cancer patients participating in four separate protocols at three institutions in Europe and the United States. Seven patients were imaged using fluoroscopy, and 39 patients were imaged using 4DCT. The magnitude of respiratory tumor motion was measured. The required treatment field margins were calculated using a statistical recipe (van Herk M, et al. Int J Radiat Oncol Biol Phys 2000;474:1121-1135), with magnitudes of all uncertainties, except respiratory peak-to-peak displacement, the same for all patients, taken from literature. Required margins for respiratory motion management were calculated using the residual respiratory tumor motion for each patient for various motion management strategies. Margin reductions for respiration management were calculated using 4DCT, 4D-IG, and gated beam delivery.nnnRESULTSnThe median tumor motion magnitude was 4.4 mm for the 46 patients (range 0-29.3 mm). This value corresponded to required treatment field margins of 13.7 to 36.3 mm (median 14.4 mm). The use of 4DCT, 4D-IG, and beam gating required margins that were reduced by 0 to 13.9 mm (median 0.5 mm), 3 to 5.2 mm (median 5.1 mm), and 0 to 7 mm (median 0.2 mm), respectively, to a total of 8.5 to 12.4 mm (median 8.6 mm).nnnCONCLUSIONnA respiratory management strategy for lung cancer radiotherapy including planning on 4DCT scans and daily image guidance provides a potential reduction of 37% to 47% in treatment field margins. The 4D image guidance strategy was the most effective strategy for >85% of the patients.

Can audio coached 4D CT emulate free breathing during the treatment course

Background. The image quality of 4DCT depends on breathing regularity. Respiratory audio coaching may improve regularity and reduce motion artefacts. We question the safety of coached planning 4DCT without coaching during treatment. We investigated the possibility of coaching to a more stable breathing without changing the breathing amplitude. The interfraction variation of the breathing cycle amplitude in free and coached breathing was studied as well as the possible impact of fatigue on longer coaching sessions. Methods. Thirteen volunteers completed respiratory audio coaching on 3 days within a 2 week period. An external marker system monitoring the motion of the thoraco-abdominal wall was used to track the respiration. On all days, free breathing and two coached breathing curves were recorded. We assumed that free versus coached breathing from day 1 (reference session) simulated breathing during an uncoached versus coached planning 4DCT, respectively, and compared the mean breathing cycle amplitude to the free versus coached breathing from day 2 and 3 simulating free versus coached breathing during treatment. Results. For most volunteers it was impossible to apply coaching without changes in breathing cycle amplitude. No significant decrease in standard deviation of breathing cycle amplitude distribution was seen. Generally it was not possible to predict the breathing cycle amplitude and its variation the following days based on the breathing in the reference session irrespective of coaching or free breathing. We found a significant tendency towards an increased breathing cycle amplitude variation with the duration of the coaching session. Conclusion. These results suggest that large interfraction variation is present in breathing amplitude irrespective of coaching, leading to the suggestion of daily image guidance for verification of respiratory pattern and tumour related motion. Until further investigated it is not recommendable to use coached 4DCT for planning of a free breathing treatment course.

Irregular breathing during 4DCT scanning of lung cancer patients: Is the midventilation approach robust?

BACKGROUNDnWith 4DCT the risk of introducing positional systematic errors in lung cancer radiotherapy can be minimised. A common approach is to plan on the phase bin of the 4DCT best representing the tumours time-weighted mean position also called the midventilation scan. However breathing irregularities can introduce uncertainties and potentially misrepresent both the tumour trajectory and the determination of the midventilation phase. In this study we evaluated the robustness of the midventilation approach in the presence of irregular breathing patterns.nnnMETHODSnA LEGO Mindstorms(®) phantom with compact balls simulating lung tumours was constructed. The breathing curves loaded in the phantom were either acquired from a human volunteer or constructed with various magnitudes (ranging from 12 to 29 mm) as well as various irregularities of motion pattern. Repeated 4DCT scans were performed while tumour trajectories were recorded with two motion tracking systems.nnnRESULTSnThe time-weighted mean tumour position is accurately represented in 4DCT scans, even for irregular breathing patterns: the position presentation in the midventilation scan was always within in one standard deviation of the global position presentation (3 mm and 2 mm for regular and irregular breathing patterns, respectively). The displacement representation tended to be underestimated in 4DCT scans.nnnCONCLUSIONnThe midventilation approach is robust even in the presence of breathing irregularity. The representation of the tumour trajectory in 4DCT scans is affected by breathing irregularity and the extent of tumour motion can be underestimated, which will affect the calculation of patient-individualised margins based on the 4DCT scan.

A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer

Abstract Background. Proton therapy of lung cancer holds the potential for a reduction of the volume of irradiated normal lung tissue. In this work we investigate the robustness of intensity modulated proton therapy (IMPT) plans to motion, and evaluate a geometrical tumour tracking method to compensate for tumour motion. Material and methods. Seven patients with a nine targets with 4DCT scans were selected. IMPT plans were made on the midventilation phase using a 3-field technique. The plans were transferred and calculated on the remaining nine phases of the 4DCT, and the combined dose distribution was summed using deformable image registration (DIR). An additional set of plans were made in which the proton beam was simply geometrically shifted to the centre of the gross tumour volume (GTV), i.e. simulating tracking of the tumour motion but without on-line adjustment of the proton energies. A possible interplay effect between the dynamics of the spot scanning delivery and the tumour motion has not been considered in this work. Results. Around 97–100% of the GTV was covered by 95% of the prescribed dose (V95) for a tumour displacement of less than about 1 cm with a static beam. For the remaining three of nine targets with a larger motion the tracking method studied provided a marked improvement over static beam; raising the GTV V95 from 95 to 100%, 82 to 98% and 51 to 97%, respectively. Conclusion. The possibility of performing DIR and summing the dose on the 4DCT data set was shown to be feasible. The fairly simplistic tracking method suggested here resulted in a marked improvement in GTV coverage for tumours with large intra-fractional motion (>1 cm displacement), indicating that on-line adjustment of the proton energies may be redundant.

Percutaneously implanted markers in peripheral lung tumours: Report of complications

Lung tumours move during breathing, and tumour motion of more than 3 cm has been seen for tumours located near the diaphragmatic domes [1]. Breath-ing-adapted radiotherapy such as respiratory beam gating or tumour tracking, rely on the ability to determine and predict the breathing-related tumour motion based on an external or internal surrogate for tumour motion [2]. The prediction of the correlation between the tumour and the surrogate positions must be verifi ed throughout the treatment; the veri-fi cation can be performed with repeated kV-imaging of the tumour. However, not all lung tumours are well-defi ned on kV-images and therefore radio-opaque markers implanted in or close to the tumour have been used as a surrogate for tumour position. Markers can be implanted percutaneously guided by fl uoroscopy or computed tomography (CT) or trans-bronchially inserted in nearby small bronchi. The advantage of percutaneous implantation is the pos-sibility to implant the marker directly into the tumour assuring a good representation of tumour motion, but potentially at the cost of morbidity due to the risk of pneumothorax. We report the results of a small pilot study examining the feasibility of CT-guided percutaneous implantation of fi ducial markers.